Download
fmicb-10-02989.pdf 3,33MB
WeightNameValue
1000 Titel
  • Vaccines and Therapeutics Against Hantaviruses
1000 Autor/in
  1. Liu, Rongrong |
  2. Ma, Hongwei |
  3. Shu, Jiayi |
  4. Zhang, Qiang |
  5. Han, Mingwei |
  6. Liu, Ziyu |
  7. Jin, Xia |
  8. Zhang, Fanglin |
  9. Wu, Xingan |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-01-30
1000 Erschienen in
1000 Quellenangabe
  • 10:2989
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fmicb.2019.02989 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002362/ |
1000 Ergänzendes Material
  • https://www.frontiersin.org/articles/10.3389/fmicb.2019.02989/full#S9 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Hantaviruses (HVs) are rodent-transmitted viruses that can cause hantavirus cardiopulmonary syndrome (HCPS) in the Americas and hemorrhagic fever with renal syndrome (HFRS) in Eurasia. Together, these viruses have annually caused approximately 200,000 human infections worldwide in recent years, with a case fatality rate of 5–15% for HFRS and up to 40% for HCPS. There is currently no effective treatment available for either HFRS or HCPS. Only whole virus inactivated vaccines against HTNV or SEOV are licensed for use in the Republic of Korea and China, but the protective efficacies of these vaccines are uncertain. To a large extent, the immune correlates of protection against hantavirus are not known. In this review, we summarized the epidemiology, virology, and pathogenesis of four HFRS-causing viruses, HTNV, SEOV, PUUV, and DOBV, and two HCPS-causing viruses, ANDV and SNV, and then discussed the existing knowledge on vaccines and therapeutics against these diseases. We think that this information will shed light on the rational development of new vaccines and treatments.
1000 Sacherschließung
lokal therapeutic strategies
lokal HFRS
lokal HPCS
lokal vaccine
lokal hantavirus
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TGl1LCBSb25ncm9uZw==|https://frl.publisso.de/adhoc/uri/TWEsIEhvbmd3ZWk=|https://frl.publisso.de/adhoc/uri/U2h1LCBKaWF5aQ==|https://frl.publisso.de/adhoc/uri/WmhhbmcsIFFpYW5n|https://frl.publisso.de/adhoc/uri/SGFuLCBNaW5nd2Vp|https://frl.publisso.de/adhoc/uri/TGl1LCBaaXl1|https://frl.publisso.de/adhoc/uri/SmluLCBYaWE=|https://frl.publisso.de/adhoc/uri/WmhhbmcsIEZhbmdsaW4=|https://frl.publisso.de/adhoc/uri/V3UsIFhpbmdhbg==
1000 Label
1000 Förderer
  1. National Natural Science Foundation of China |
  2. Key Research and Development Projects of Shaanxi Province |
1000 Fördernummer
  1. 81772167; 81971563; 81602494; 81671994
  2. 2019ZDLSF02-03
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
  1. Vaccines and Therapeutics Against Hantaviruses
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer National Natural Science Foundation of China |
    1000 Förderprogramm -
    1000 Fördernummer 81772167; 81971563; 81602494; 81671994
  2. 1000 joinedFunding-child
    1000 Förderer Key Research and Development Projects of Shaanxi Province |
    1000 Förderprogramm -
    1000 Fördernummer 2019ZDLSF02-03
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6422330.rdf
1000 Erstellt am 2020-08-05T11:49:48.921+0200
1000 Erstellt von 24
1000 beschreibt frl:6422330
1000 Bearbeitet von 122
1000 Zuletzt bearbeitet 2020-08-05T14:59:41.671+0200
1000 Objekt bearb. Wed Aug 05 11:51:30 CEST 2020
1000 Vgl. frl:6422330
1000 Oai Id
  1. oai:frl.publisso.de:frl:6422330 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source